publication venue for
- ACTIVATE: A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MITAPIVAT IN ADULTS WITH PYRUVATE KINASE DEFICIENCY WHO ARE NOT REGULARLY TRANSFUSED 2021
- PROSPECTIVE STUDY OF THE IMMUNOLOGICAL RES PONSE TO FACTOR VIII IN SEVERE HEMOPHILIA A PATIENTS DURING IMMUNE TOLERANCE INDUCTION TREATMENT 2019
- RFVIIIFC FOR FIRST-TIME IMMUNE TOLERANCE INDUCTION (ITI) THERAPY: INTERIM RESULTS FROM THE GLOBAL, PROSPECTIVE VERITI-8 STUDY 2019
- MIR-22 SERUM A NEW NON INVASIVE PROGNOSTIC MARKER IN PATIENTS AFFECTED BY DIFFUSE LARGE B CELL LYMPHOMA: PRELIMINARY RESULTS OF A PROSPECTIVE STUDY 2018
- LIQUID BIOPSY: DECIPHERING A SIGNATURE OF CIRCULATING MICRORNAS AS NOVEL NON-IVASIVE BIOMARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA. PRELIMINARY RESULTS OF A PROSPECTIVE STUDY 2017
- DEVELOPMENT OF A SCREENING AND DIAGNOSTIC ALGORITHM FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA USING A MODIFIED DELPHI PANEL METHODOLOGY 2017
- DOES EARLY RESPONSE TO FIRST LINE CORTICOSTEROID THERAPY PREDICT REQUIREMENT FOR SECOND LINE THERAPY IN IMMUNE THROMBOCYTOPENIA 2017
- LIQUID BIOPSY: DECIPHERING A SIGNATURE OF CIRCULATING MICRORNAS AS NOVEL NON-INVASIVE BIOMARKERS IN DIFFUSE LARGE B-CELL LYMPHOMA 2017
- CONSTRUCTION OF A DECISION MODEL TO AID TREATMENT CHOICES FOR EARLY STAGE HODGKIN LYMPHOMA: BRINGING SURVIVORSHIP FORWARD 2016
- A PHASE 1B/2 STUDY OF SELINEXOR IN COMBINATION WITH BACKCONE THERAPIES FOR TREATMENT OF RELAPSED/REFACTORY MULTIPLE MYELOMA 2016
- IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY 2016
- ENESTCMR 4-Y RESULTS: PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND RESIDUAL DISEASE MORE LIKELY TO ACHIEVE DEEP MOLECULAR RESPONSE FOLLOWING SWITCH TO NILOTINIB (NIL) 2015
- IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY 2015
- OPTIMAL DURATION OF ANTICOAGULANT THERAPY FOR THE TREATMENT OF CANCER-ASSOCIATED THROMBOSIS 2015
- ANTI-TUMOR ACTIVITY OF SELINEXOR (KPT-330), AN ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE), +/- DEXAMETHASONE IN MULTIPLE MYELOMA PRECLINICAL MODELS & TRANSLATION IN PATIENTS WITH MULTIPLE MYELOMA 2014
- EARLY MOLECULAR RESPONSE PREDICTS ACHIEVEMENT OF UNDETECTABLE BCR-ABL IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH NILOTINIB: 3-YEAR FOLLOW-UP OF ENESTCMR 2014
- THE IMPACT OF BLEEDING COMPLICATIONS IN PATIENTS RECEIVING NOVEL ORAL ANTICOAGULANTS: A SYSTEMATIC REVIEW AND META-ANALYSIS 2014
- DOSE-ESCALATION AND PHARMACOKINETICS (PK) OF DIFFERENT LENALIDOMIDE (LEN) STARTING DOSE REGIMENS IN PATIENTS WITH RELAPSED OR REFRACTORY (REL/REF) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) (CC-5013-CLL-009) 2013
- THE USE OF PREOPERATIVE ERYTHROPOIESIS-STIMULATING AGENTS ( ESAS) IN PATIENTS WHO UNDERWENT KNEE OR HIP ARTHROPLASTY 2013
- END OF TREATMENT BUT NOT INTERIM PET SCAN PREDICTS OUTCOME IN NON-BULKY LIMITED STAGE HODGKIN LYMPHOMA 2010
- IDIOPATHIC VEIN THROMBOSIS: IDENTIFICATION OF POPULATIONS AT DIFFERENT RISK OF RELAPSE FOLLOWING ORAL ANTICOAGULANT TREATMENT. THE RESULTS OF THE 'EXTENDED-DACUS STUDY' 2010
- PREVALENCE AND DETERMINANTS OF BLEEDING IN SEVERE VON WILLEBRAND DISEASE TYPE 3: RESULTS OF RETRO/PROSPECTIVE STUDIES IN A COHORT OF 105/52 ITALIAN PATIENTS 2010
- A CONDITIONAL KNOCK-IN ALLELE OF THE TYPE A CYTOPLASMIC NUCLEOPHOSMIN MUTATION COOPERATES WITH A NOVEL SLEEPING BEAUTY TRANSPOSON TO CAUSE ACUTE MYELOID LEUKAEMIA IN MICE 2010
- IDIOPATHIC VEIN THROMBOSIS: IDENTIFICATION OF POPULATIONS AT DIFFERENT RISK OF RELAPSE FOLLOWING ORAL ANTICOAGULANT TREATMENT. THE RESULTS OF THE 'EXTENDED-DACUS STUDY' 2010
- PREVALENCE AND DETERMINANTS OF BLEEDING IN SEVERE VON WILLEBRAND DISEASE TYPE 3: RESULTS OF RETRO/PROSPECTIVE STUDIES IN A COHORT OF 105/52 ITALIAN PATIENTS 2010
- PROFILING OF MICRORNA EXPRESSION IN PURIFIED HEMATOPOIETIC POPULATIONS AND IN SINGLE CELLS 2010
- COMPARATIVE ANALYSIS OF SHWACHMAN-DIAMOND SYNDROME TO OTHER INHERITED MARROW FAILURE SYNDROMES 2009
- GENETIC ANALYSIS OF INHERITED BONE MARROW FAILURE SYNDROMES FROM ONE COMPREHENSIVE COHORT OF PATIENTS 2009
- MALIGNANT MYELOID TRANSFORMATION IN INHERITED BONE MARROW FAILURE SYNDROMES 2009
- THE IMPACT OF DEEP VEIN THROMBOSISON ON OUTCOMES IN CRITICALLY ILL PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS 2008
- THE IMPACT OF DEEP VEIN THROMBOSISON ON OUTCOMES IN CRITICALLY ILL PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS 2008
- EFFECT OF FONDAPARINUX 2.5 MG ONCE DAILY ON ALL CAUSE MORTALITY: A META-ANALYSIS OF THROMBOPROPHYLAXIS TRIALS 2008
- EFFECT OF FONDAPARINUX 2.5 MG ONCE DAILY ON ALL CAUSE MORTALITY: A META-ANALYSIS OF THROMBOPROPHYLAXIS TRIALS 2008
- PERIOPERATIVE MANAGEMENT OF ANTICOAGULATION WITH TAPERED DOSE WARFARIN 2008
- PHARMACOKINETICS (PK) OF SUBCUTANEOUS FONDAPARINUX 1.5 MG IN PATIENTS WITH MODERATE RENAL IMPAIREMENT (MRI) 2008
- Pharmacokinetics of the reformulated B-DOMAIN deleted recombinant factor VIII (BDD-RFVIII) concentrate using chromogenic and one-stage assays with pooled normal plasma (PNP) and refacto laboratory standard (RLS) 2007
- High interleukin-15 expression levels in initial diagnostic leukemic cells of children with acute lymphoblastic leukemia are associated with subsequent relapse involving the central nervous system 2007
- Outcomes ofthrombolysis for repeated courses of systemic tissue plasminogen activator for intravascular thrombosis in children 2007
- Pharmacokinetics of the reformulated B-domain deleted recombinant factor VIII concentrate using chromogenicand one-stage assays with pooled normal plasma and refacto laboratory standard 2007
- The preliminary report for the early prediction of therapeutic response in multiple myeloma patients by interim 18F-FDG-PET/CT 2007
- Overview of the clinical results of pentasaccharide in major orthopedic surgery 2001
- Humanized zebrafish enhance human hematopoietic stem cell survival and promote acute myeloid leukemia clonal diversity.. 105:2391-2399. 2020
- The risk of bleeding in thrombocytopenic patients with acute myeloid leukemia. 91:1530-1537. 2006
- Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. 91:976-979. 2006
- Determining the cause of patchwork HBA1 and HBA2 genes: recurrent gene conversion or crossing over fixation events. 91:297-302. 2006